Global push to improve MND and ALS cures by PRISM ALS consortium
This image was generated by AI and may not depict real events.
A global consortium called PRISM ALS has been launched to develop patient-derived stem cell models for amyotrophic lateral sclerosis (ALS) and motor neurone disease (MND) research. The initiative aims to improve the accuracy of ALS modelling and accelerate the development of effective treatments by providing high-quality, accessible stem cell models.
The PRISM ALS consortium is a collaborative effort between the ALS Therapy Development Institute, LifeArc, and Axol Bioscience. The goal is to develop patient-derived stem cell models that better reflect the biological complexity of ALS. Current cell models used for testing treatments do not accurately represent the diverse nature of the disease. The PRISM ALS initiative will provide a reliable source of sporadic ALS/MND models for research. ALS is a heterogeneous disease, with 85% of cases being sporadic. The consortium will enable standardised production of stem cell models at scale, ensuring quality and consistency across laboratories.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.